Cargando…
Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients
INTRODUCTION: There is an unmet medical need for pruritus associated with chronic kidney disease, a distressing complication characterized by generalized and persistent itch affecting 20% to 40% of patients undergoing hemodialysis. Here we report the results of a phase 2 trial evaluating the efficac...
Autores principales: | Fishbane, Steven, Mathur, Vandana, Germain, Michael J., Shirazian, Shayan, Bhaduri, Sarbani, Munera, Catherine, Spencer, Robert H., Menzaghi, Frédérique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210745/ https://www.ncbi.nlm.nih.gov/pubmed/32405581 http://dx.doi.org/10.1016/j.ekir.2020.01.006 |
Ejemplares similares
-
Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study
por: Weiner, Daniel E., et al.
Publicado: (2022) -
Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program
por: Fishbane, Steven, et al.
Publicado: (2022) -
Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies
por: Topf, Joel, et al.
Publicado: (2022) -
Assessment of the physical dependence potential of difelikefalin: Randomized placebo‐controlled study in patients receiving hemodialysis
por: Spencer, Robert H., et al.
Publicado: (2023) -
Pharmacokinetics, Metabolism, and Excretion of Intravenous [14C]Difelikefalin in Healthy Subjects and Subjects on Hemodialysis
por: Stark, Jeffrey G., et al.
Publicado: (2023)